Clinical evidence also suggests that patients with hypermethylation on the promoter region of tumor suppressive genes, such as Ras association domain family member 1 (RASSF1A) 35, BRMS133, and breast cancer type 1 susceptibility gene (BRCA1) 36, 37, 38, are associated with poor prognosis. This evidence concerns the gene RASSF1 and neoplasm.